Applied Therapeutics Inc is a biopharmaceutical company committed to developing transformative treatments for patients with unmet medical needs. The company focuses on targeting specific biological pathways to address diseases where there is a significant unmet medical need, primarily in the field of metabolic diseases. Their corporate philosophy revolves around innovation, collaboration, and patient-centricity. Applied Therapeutics Inc aims to revolutionize treatment options and improve outcomes for patients by combining scientific expertise with cutting-edge technology. By continuously advancing their research and development efforts, Applied Therapeutics Inc strives to provide hope and better quality of life for individuals affected by metabolic diseases.

Applied Therapeutics Inc is primarily present in the United States.

Over the years, Applied Therapeutics Inc has achieved several significant milestones. Notably, the company successfully completed its initial public offering (IPO) in May 2019, marking a major step towards growth and expansion. Additionally, Applied Therapeutics has made significant progress in its clinical development programs, particularly with its lead drug candidate, AT-001. The company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for AT-001's investigation in Diabetic Cardiomyopathy patients. These accomplishments demonstrate Applied Therapeutics Inc's commitment to advancing innovative therapies and its dedication to improving the lives of patients.

Applied Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of serious diseases. Founded in 2016, the company is based in New York City, and it utilizes innovative science to target molecular pathways involved in various diseases. Applied Therapeutics is dedicated to addressing unmet medical needs and improving patients' lives through its drug development programs. With a strong focus on research and development, the company aims to bring innovative and life-changing therapies to market. Applied Therapeutics Inc continues to grow and advance its pipeline, demonstrating its commitment to improving healthcare outcomes.

The main competitors of Applied Therapeutics Inc in the market include other pharmaceutical companies such as Biogen Inc, Pfizer Inc, and Eli Lilly and Company.

Applied Therapeutics Inc is primarily active in the pharmaceutical industry.

Applied Therapeutics Inc. operates under a business model focused on developing and commercializing novel therapeutics to address unmet medical needs. With a strong focus on molecular insights and cutting-edge technology, the company aims to identify and target specific diseases at the molecular level. Applied Therapeutics Inc. invests in research and development to advance its pipeline of potential drug candidates for various conditions such as diabetic cardiomyopathy and galactosemia. By leveraging their expertise in drug discovery and development, the company strives to improve patient outcomes and offer innovative treatment options.

Applied Therapeutics KGV ir -6,32.

Applied Therapeutics KUV ir 357,29.

AlleAktien kvalitātes vērtējums Applied Therapeutics ir 3/10.

gaidāmā Applied Therapeutics apgrozījums ir 1,98 milj. USD.

gaidāmā Applied Therapeutics peļņa ir -112,17 milj. USD.

Applied Therapeutics Inc. is an emerging pharmaceutical company focused on developing medical therapies for patients with rare diseases. The company's business model is based on identifying genetic risk factors and developing drugs that target these specific diseases. They focus on optimizing therapy through personalized medicine to maximize success and minimize costs. The company is focused on the discovery, development, and marketing of medications, with a strong emphasis on discovering new therapeutic targets and developing molecules that target them. They also prioritize the development of innovative formulations that improve drug absorption and efficacy, particularly through nanotechnology approaches. Applied Therapeutics already has several products in the pipeline targeting different genetic defects and alleviating symptoms in affected patients. They have developed an online tool to help doctors and patients better understand the genetic causes of diseases. Overall, their business model is characterized by clinical and scientific innovations, as well as personalized medicine developments. They will make a significant contribution to improving the effectiveness of therapies in treating rare diseases through their work in targeted genetics.

Applied Therapeutics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Applied Therapeutics vai uzņēmums nedod dividendes.

Applied Therapeutics ISIN ir US03828A1016.

Applied Therapeutics WKN ir A2PHHB.

Applied Therapeutics simbols ir APLT.

Pēdējo 12 mēnešu laikā Applied Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Applied Therapeutics plāno maksāt dividendes 0 USD apmērā.

Applied Therapeutics pašreizējā dividendu rentabilitāte ir .

Applied Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Applied Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Applied Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Applied Therapeutics apmērā 0 USD, kas tika izmaksāta 27.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 27.09.2024..

Pēdējās dividendes izmaksa notika 27.09.2024..

Gadā 2023, Applied Therapeutics izmaksāja 0 USD dividendes.

Applied Therapeutics dividendes tiek izmaksātas USD.